NASDAQ:CRDL Cardiol Therapeutics Q2 2026 Earnings Report $1.27 +0.04 (+3.24%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cardiol Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/ACardiol Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACardiol Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Cardiol Therapeutics Earnings HeadlinesCardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC TrialJuly 14, 2026 | tipranks.comCardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart AssociationJuly 14, 2026 | prnewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 21 at 1:00 AM | Banyan Hill Publishing (Ad)Cardiol Therapeutics to Highlight CardiolRx Programs at B. Riley Mind, Muscle & Vision SummitJuly 9, 2026 | tipranks.comCardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision SummitJuly 9, 2026 | prnewswire.comCardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of ShareholdersJune 26, 2026 | finanznachrichten.deSee More Cardiol Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email. Email Address About Cardiol TherapeuticsCardiol Therapeutics (NASDAQ:CRDL) Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease. CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes. The company is preparing to initiate further Phase 2 trials in patients with heart failure and preserved ejection fraction to explore the potential of CBD-based therapy to reduce hospitalization rates and improve quality of life. In parallel, Cardiol is investigating novel cyclic dinucleotide immunomodulators designed to recalibrate the innate immune response in cardiovascular settings. Headquartered in Toronto, Canada, Cardiol Therapeutics operates multiple clinical and research collaborations across North America and Europe. Founded in 2017 and rebranded in 2019 after acquiring its core CBD assets, the company is led by Executive Chairman Peter Hamilton, a seasoned life-science executive, alongside a management team with deep expertise in drug development, regulatory affairs, and cardiovascular research. Cardiol’s strategy emphasizes translational science and collaborative clinical programs to address critical unmet needs in heart disease.View Cardiol Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity?IBM Just Had Its Worst Day Ever—What Earnings Must ProveMeta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
